| Literature DB >> 29429859 |
Mangalakumari Jeyanathan1, Yushi Yao1, Sam Afkhami1, Fiona Smaill2, Zhou Xing3.
Abstract
Despite some major progress made in developing tuberculosis (TB) vaccine strategies, with a dozen novel vaccines currently in the clinical pipeline, the world is still missing an effective TB vaccine. This questions whether any major breakthroughs can be achieved without making a drastic departure from the current strategy, which creates a state of 'near-natural immunity', imitating the natural immunity developed after Mycobacterium tuberculosis (Mtb) infection. Here, we argue instead that mounting evidence suggests an effective strategy ought to induce a state of all-around 'un-natural' immunity comprising trained innate immunity (TII), tissue-resident memory T cells (TRM), and anti-Mtb surface antibodies in the lung. Thus, here we summarize the latest information, thinking, and development in the field of TB and vaccines.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29429859 DOI: 10.1016/j.it.2018.01.006
Source DB: PubMed Journal: Trends Immunol ISSN: 1471-4906 Impact factor: 16.687